Developing therapeutic cancer vaccines

Press releases & announcements

18 September, 2018

RhoVac recruits Steven Glazer as Medical Director

RhoVac AB (“RhoVac”) announced today, September 18, 2018, that the company has recruited Dr. Steven Glazer to the position of Medical Director (MD), commencing immediately. Steven Glazer has been recruited... [Read more]

17 August, 2018

RhoVac AB participates in two international conferences and several investment events in Sweden

RhoVac AB (“RhoVac”) announces today that it will attend Nordic Life Science Days, Stockholm in September and at BIO-Europe, Copenhagen in November. The company will also attend three investment events... [Read more]

1 August, 2018

RhoVac’s reports positive results in the company’s phase I/II clinical study

RhoVac AB (“RhoVac”) reported today, August 1, 2018, positive top-line results on safety and on immune activation in their phase I/II clinical trial RhoVac-001 in prostate cancer patients. In totally... [Read more]

Press Releases and Company Announcements published before 1 May 2017 in Swedish only.

RhoVac in Brief

RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.

Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.

More about RhoVac